With $4.1 million in the bank as of June 30, Antisense is well placed to fund the regulatory aspects leading up to the phase 2b trial, but the trial itself would necessitate further capital.“We’ve got a bit of time to think over the options,” Mr Diamond says.
“We also have pharma company interest in the program, even though we have not been actively out there seeking it.”With the pending FDA ‘orphan’ drug decision and the European trial plans unfolding, investors might not have to wait long to for more potential catalysts
The above by Tim Boreham..
Article the Anp story.. De risked
. Pharma interest
. FDA Orphan drug designation imminent...$$$
The Rome Cohort, page-80
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $85.01M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $103.7K | 1.237M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 204084 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.5¢ | 280000 | 3 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |